Fair Value of Financial Instruments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 15, 2024	Aug. 31, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 08, 2022
Fair Value, Option, Quantitative Disclosures [Line Items]
Unrealized gain (loss) on investment in equity securities				$ 75,492	$ 0
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]				General and administrative
Change in fair value of the contingent financial asset and contingent financial liabilities				$ 100
Changes in fair value of contingent assets and liabilities				1,405	$ 9,475
2.625% Convertible Senior Notes due 2027 | Convertible Debt
Fair Value, Option, Quantitative Disclosures [Line Items]
Share price (in dollars per share)						$ 56.01
Long-term debt			$ 575,000	575,000
Debt instrument, fair value			892,400	892,400
Progenics
Fair Value, Option, Quantitative Disclosures [Line Items]
Payments for prior acquisition				85,000
Progenics | Net Sales Targets for Azedra
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high			70,000	70,000
Progenics | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high			5,000	5,000
Progenics | 1404 Commercialization Milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high			$ 10,000	$ 10,000
Progenics | Reduction due to partial settlement of 2013 Milestone Rights
Fair Value, Option, Quantitative Disclosures [Line Items]
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			General and administrative
Change in fair value of the contingent financial asset and contingent financial liabilities			$ (1,500)
Changes in fair value of contingent assets and liabilities		$ 1
Radiopharm Theranostics Limited
Fair Value, Option, Quantitative Disclosures [Line Items]
Share price (in dollars per share)	$ 0.03		$ 0.02	$ 0.02
Unrealized gain (loss) on investment in equity securities			$ (2,100)	$ (2,100)
Equity investment, shares (in shares)	149,625,180			149,625,180
Equity Method Investments, Fair Value Disclosure			$ 2,900	$ 2,900
Perspective Therapeutics, Inc
Fair Value, Option, Quantitative Disclosures [Line Items]
Shares owned (in shares)	11,677,339		11,677,339	11,677,339
Investment owned, fair value			$ 155,900	$ 155,900
Share price (in dollars per share)			$ 13.35	$ 13.35
Unrealized gain (loss) on investment in equity securities			$ 39,500	$ 77,600